Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 195Magnetic Resonance Spectroscopy 154pembrolizumab 152Carboplatin 115Biopsy 110Cyclophosphamide 100Cisplatin 88Paclitaxel 80Gemcitabine 72Bevacizumab 70fludarabine 61Nivolumab 60Radiotherapy 52Fluorouracil 52Capecitabine 49Dexamethasone 48Pemetrexed 46Rituximab 44Oxaliplatin 44Docetaxel 44Leucovorin 43atezolizumab 42Doxorubicin 42venetoclax 39durvalumab 39Standard of Care 34Prednisone 34Temozolomide 33Radiation 33Cetuximab 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Biosimilar Pharmaceuticals × 30 days × Clear all
NCT03564340 2026-05-08

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
890 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07220135 2026-05-06

NeoTHERa

University of Kansas Medical Center

Phase 2 Recruiting
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡